Please use this identifier to cite or link to this item: http://hdl.handle.net/11452/24943
Title: Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma
Authors: Sezgin, Canfeza
Veral, Ali
Karabulut, Bülent
Göker, Erdem
Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.
0000-0002-2382-290X
0000-0003-2501-3097
0000-0002-9732-5340
Kurt, Ender
Evrensel, Türkkan
Yalçınkaya, Ülviye
Kanat, Özkan
Demiray, Mutlu
Arslan, Murat
Ercan, İlker
Manavoǧlu, Osman
M-8060-2019
AAJ-1027-2021
7006207332
6603942124
6508300295
55881548500
6603631569
57197925370
6603789069
6602587152
Keywords: General & internal medicine
Pharmacology & pharmacy
Extrapulmonary
Small cell carcinoma
Therapy
C-kit
Single-institution experience
Lung-cancer
Protein expression
Phase-II
Chemotherapy
Bladder
Overexpression
Prognosis
Diagnosis
Imatinib
Issue Date: May-2005
Publisher: Wiley
Citation: Kurt, E. vd. (2005). "Therapy, outcome and analysis of c-kit expression in patients with extrapulmonary small cell carcinoma". International Journal of Clinical Practice, 59(5), 537-543.
Abstract: In this study, we aimed to investigate the clinicopathological characteristics with special emphasis on c-kit expression and the treatment results of patients with extrapulmonary small cell carcinoma (EPSCC). The medical records of the patients with EPSCC were reviewed, and the data regarding patient and tumour characteristics, treatment and clinical outcome were retrieved and analysed. A total of 28 patients with the diagnosis of EPSCC were identified. There were 19 males and 9 females, with a mean age of 56.5 years. Patients with limited disease (LD) (n = 13) were treated with surgery, chemotherapy (CT) and radiotherapy with different sequences. Patients with extensive disease (ED) (n = 15) were mainly treated with combination CT. The median overall survival was 14.5 months in patients with LD compared to 11 months in those with ED (p = 0.029). Ten patients (36%) showed c-kit overexpression. There was no significant difference between the survival of c-kit-positive and c-kit-negative patients (p = 0.367). In conclusion, our study demonstrates that the prognosis of EPSCC is poor despite currently available treatments. C-kit may be considered as a potential target for novel therapeutical approaches.
URI: https://doi.org/10.1111/j.1368-5031.2005.00447.x
https://onlinelibrary.wiley.com/doi/10.1111/j.1368-5031.2005.00447.x
https://pubmed.ncbi.nlm.nih.gov/15857349/
http://hdl.handle.net/11452/24943
ISSN: 1368-5031
Appears in Collections:PubMed
Scopus
Web of Science

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons